As a leading innovator in health technology, managing one of the strongest and largest IP portfolios in the world, Philips licenses some of its innovative technologies to third parties. NLC and Philips have recently teamed up to create new ventures based on Philips’ IP, and the first venture has now been established: Hemeo is developing decision support software to help doctors in the ICU prevent and treat problems with blood clotting, both too much clotting (thrombosis) and too little (bleeding). Coagulation disorders are a major source of medical complications and high healthcare costs. Hemeo aims to make it much easier for doctors to follow the complex protocols for coagulation disorders and, based on AI-enabled decision support, promises to be attuned to the individual patient more specifically and therefore better.